A Retrospective Study of the Management of Chinese Melasma Patients Using a 1927 Nm Fractional Thulium Fiber Laser
Overview
Affiliations
Background: A new fractional photothermolysis device is used in our retrospective study to treat melasma in Chinese patients.
Objectives: To evaluate the efficacy and safety of the 1927 nm fractional thulium fiber laser in the treatment of melasma in Chinese patients.
Methods: Eleven melasma patients who received treatment between November 2009 and May 2010 were included. Photographic images at baseline and follow-up were assessed for clinical efficacy and complications by two independent and blinded physicians. Questionnaires were also completed by patients.
Results: Significant MASI improvements were seen at 1 week, 1 month and 2 months, but not at 3 months. Patients' degree of satisfaction was high. Significant improvement in skin texture and pore size was seen for up to 2 months and improvement in wrinkles for up to a month. There was no change in skin laxity. Main adverse effects seen were erythema, edema, and crusting in the early days. One patient developed PIH.
Conclusion: The novel 1927 nm fractional thulium fiber laser is safe and effective in the management of melasma in Chinese patients for up to 2 months. It is also useful in photo-rejuvenation. Complications were limited to erythema and edema in the early days, and transient PIH.
In Vivo Histological Study Evaluating Non-Ablative Fractional 1940-nm Laser.
Schallen K, Seder M, Jorgenson M, Schomacker K, Bhawan J Lasers Surg Med. 2024; 57(1):54-62.
PMID: 39279229 PMC: 11776451. DOI: 10.1002/lsm.23842.
Kim K, Jeong J, Jo J, Ryu H, Kim I Lasers Med Sci. 2023; 38(1):262.
PMID: 37947906 DOI: 10.1007/s10103-023-03928-6.
Tao J, Champlain A, Weddington C, Moy L, Tung R Scars Burn Heal. 2018; 4:2059513118758510.
PMID: 29799583 PMC: 5965338. DOI: 10.1177/2059513118758510.
Lasers in Melasma: A Review with Consensus Recommendations by Indian Pigmentary Expert Group.
Sarkar R, Aurangabadkar S, Salim T, Das A, Shah S, Majid I Indian J Dermatol. 2017; 62(6):585-590.
PMID: 29263531 PMC: 5724305. DOI: 10.4103/ijd.IJD_488_17.